New combo aims to tame MALT lymphoma with less radiation damage
NCT ID NCT07554898
First seen Apr 30, 2026 · Last updated Jun 22, 2026 · Updated 11 times
Summary
This phase 2 trial is testing a new approach for adults with early-stage (I-II) MALT lymphoma, a slow-growing cancer. Participants first receive a very low dose of radiation (4 Gy total) over two days, then take a daily targeted drug called orelabrutinib for up to 6 months. The goal is to improve cancer remission while reducing long-term side effects like dry mouth or cataracts that can occur with standard radiation. The study will enroll 60 people across multiple centers to see how well the treatment works and how safe it is.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALT LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
No. 1, East Banshan Road , Gongshu District
RECRUITINGHangzhou, Zhejiang, 310000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital, Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Orelabrutinib (a targeted drug) and ultra-low-dose radiation therapy
What this could lead to
If successful, this approach could offer a more effective and less toxic first-line treatment for early-stage MALT lymphoma, potentially reducing long-term side effects from standard radiation.
What could go wrong
This is a small, early-phase (phase 2) study with only 60 participants. The combination may not work better than existing treatments, and orelabrutinib can cause side effects like infections or bleeding. Long-term benefits and risks are still unknown.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.